Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV101 for weight loss in obesity
NCT06979505Phase 2Completed
- Sponsor
- Graviton Biosciences
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of TDI01 in obesity (3 arms), sponsored by Graviton Biosciences. Primary endpoint: Mean Percent Change in Body Weight from Baseline at 16 weeks. Started Jun 2025; status: completed.
02
Drugs
TDI01
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06979505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979505.